RF&L Wealth Management’s AbbVie ABBV Stock Holding History

RF&L Wealth Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.13M	Sell	8,470 -250	-3%	-$53.8K	1.44%	19
2026 Q1	$1.9M	Sell	8,720 -8,286	-49%	-$1.84M	1.42%	19
2025 Q4	$3.89M	Sell	17,006 -144	-0.8%	-$32.8K	2.18%	18
2025 Q3	$3.97M	Sell	17,150 -410	-2%	-$83.5K	2.33%	17
2025 Q2	$3.26M	Sell	17,560 -170	-1%	-$31.6K	2.1%	18
2025 Q1	$3.71M	Sell	17,730 -200	-1%	-$38.9K	2.66%	16
2024 Q4	$3.19M	Sell	17,930 -250	-1%	-$46K	2.25%	16
2024 Q3	$3.59M	Sell	18,180 -250	-1%	-$46.7K	2.54%	16
2024 Q2	$3.16M	Hold	18,430	–	–	2.41%	17
2024 Q1	$3.36M	Sell	18,430 -500	-3%	-$86.2K	2.58%	15
2023 Q4	$2.93M	Sell	18,930 -95	-0.5%	-$13.8K	2.44%	14
2023 Q3	$2.84M	Hold	19,025	–	–	2.63%	14
2023 Q2	$2.56M	Sell	19,025 -300	-2%	-$44K	2.34%	14
2023 Q1	$3.08M	Sell	19,325 -455	-2%	-$69.6K	2.99%	11
2022 Q4	$3.2M	Buy	+19,780	New	+$3.03M	3.29%	10

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

RF&L Wealth Management's ABBV Position: Q2 2026 in Review

RF&L Wealth Management reduced its AbbVie (ABBV) stake by 2.9% in Q2 2026, selling an estimated $53.8K and leaving 8,470 shares worth $2.13M. The position accounts for 1.44% of the portfolio, ranked #19.

RF&L Wealth Management first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. The position peaked at $3.97M in Q3 2025. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

RF&L Wealth Management held 8,470 shares of AbbVie worth $2.13M as of Q2 2026.
RF&L Wealth Management sold 250 AbbVie shares in Q2 2026, an estimated $53.8K.
AbbVie made up 1.44% of RF&L Wealth Management's portfolio in Q2 2026, its #19 holding.
RF&L Wealth Management first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
RF&L Wealth Management's AbbVie position peaked at $3.97M in Q3 2025.
4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on RF&L Wealth Management's 13F filing for Q2 2026, filed 22 Jul 2026.